Molecular Therapy Advances

Engineered virus delivers genes broadly in monkey retinas

An AI-designed virus delivered a marker gene across a broader retinal area than a comparison virus in monkeys examined after 21 days.

Studied:
Experiments in mice
What changed:
The engineered virus drove broader fluorescent protein expression across monkey retinas than AAV2.7m8
The catch:
Excluding monkeys with AAV2-neutralizing antibodies favors animals receptive to gene delivery
Stake:
Cyagen Biosciences funded the study.

Editor of record: Boris Djordjevic · AgingResearch.News

Follow @agingbrief

Non-human primates received injections into the eye’s gel-filled interior in an animal experiment testing AAV2.PN168, an engineered adeno-associated virus used to carry genes into cells. Researchers used artificial intelligence to design its outer shell. After 21 days, a marker protein appeared across a broader area of the retina, the eye’s light-sensing layer, than with another engineered virus.

In separate experiments, mice of both sexes aged 6–8 weeks also showed broad retinal gene delivery. In mice modeling Leber’s congenital amaurosis type 1, an inherited eye disease, delivery of a therapeutic gene improved retinal electrical responses, with effects still evident 56 days after injection. In mice modeling wet age-related macular degeneration, delivery of an antibody fragment reduced leakage beneath the retina over 21 days.

Why it matters

Wet age-related macular degeneration can impair vision through abnormal blood vessel growth. The authors suggest the engineered virus has potential for treating this and other retinal degenerations.

Caveats

The monkey experiments measured gene delivery, not disease improvement. Therapeutic benefits were tested in genetically engineered mice aged 6–8 weeks, not people with retinal disease.

Comments

Be the first to comment.